HONG KONG – Chinese biopharmaceutical firm Beigene Ltd. filed with the Hong Kong Stock Exchange (HKEX) for a monster IPO that could raise more than $1 billion. It is the second biotech firm to seek an HKEX listing after Hangzhou-based Ascletis Pharma Inc. priced a nearly $400 million offering earlier this month.